FR2774596B1 - Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer - Google Patents

Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer

Info

Publication number
FR2774596B1
FR2774596B1 FR9801591A FR9801591A FR2774596B1 FR 2774596 B1 FR2774596 B1 FR 2774596B1 FR 9801591 A FR9801591 A FR 9801591A FR 9801591 A FR9801591 A FR 9801591A FR 2774596 B1 FR2774596 B1 FR 2774596B1
Authority
FR
France
Prior art keywords
selenated
alzheimer
disease
prevention
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9801591A
Other languages
English (en)
Other versions
FR2774596A1 (fr
Inventor
Marie Claude Burgevin
Norbert Dereu
Assunta Imperato
Mrabet Saliha Moussaoui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to FR9801591A priority Critical patent/FR2774596B1/fr
Priority to PCT/FR1999/000264 priority patent/WO1999040911A1/fr
Priority to AU44809/99A priority patent/AU4480999A/en
Publication of FR2774596A1 publication Critical patent/FR2774596A1/fr
Application granted granted Critical
Publication of FR2774596B1 publication Critical patent/FR2774596B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR9801591A 1998-02-11 1998-02-11 Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer Expired - Fee Related FR2774596B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR9801591A FR2774596B1 (fr) 1998-02-11 1998-02-11 Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
PCT/FR1999/000264 WO1999040911A1 (fr) 1998-02-11 1999-02-08 Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
AU44809/99A AU4480999A (en) 1998-02-11 1999-02-08 Use of selenium compounds for preventing and treating Alzheimer disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9801591A FR2774596B1 (fr) 1998-02-11 1998-02-11 Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
FR2774596A1 FR2774596A1 (fr) 1999-08-13
FR2774596B1 true FR2774596B1 (fr) 2000-03-17

Family

ID=9522828

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9801591A Expired - Fee Related FR2774596B1 (fr) 1998-02-11 1998-02-11 Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer

Country Status (3)

Country Link
AU (1) AU4480999A (fr)
FR (1) FR2774596B1 (fr)
WO (1) WO1999040911A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013205053B2 (en) * 2005-10-14 2015-07-23 Alltech, Inc. Method and compositions for altering cell function
CN102764279B (zh) * 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
JP5616631B2 (ja) * 2006-04-24 2014-10-29 オルテック インコーポレイテッド 細胞機能を変化させるための方法および組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
DE3937170A1 (de) * 1989-11-08 1991-05-16 Nattermann A & Cie Benzylselenobenzamide von aminopyridinen und picolylaminen
DE3937171A1 (de) * 1989-11-08 1991-05-16 Nattermann A & Cie Picolylselenobenzamide von aminopyridinen, anilinen und picolylaminen
DE3937169A1 (de) * 1989-11-08 1991-05-16 Nattermann A & Cie Benzylselenobenzamide von anilinen und benzylaminen
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
SE9302333D0 (sv) * 1993-07-06 1993-07-06 Ab Astra New compounds

Also Published As

Publication number Publication date
AU4480999A (en) 1999-08-30
WO1999040911A1 (fr) 1999-08-19
FR2774596A1 (fr) 1999-08-13

Similar Documents

Publication Publication Date Title
EP0963219A4 (fr) Manipulations de stress nitrosant et oxydatif dans le traitement d'une maladie
EP1007048A4 (fr) Identification d'agents utiles dans le traitement de la maladie d'alzheimer
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
FI962557L (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
PL348226A1 (en) Compounds for the antemortem diagnosis of alzheimer's disease and in vivo
IT9083334A0 (it) Procedimento per l'estrazione e la purificazione di dna genomico umano
FI964284L (fi) Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito
EP0667769A4 (fr) Utilisation de composes specifiques alpha-1c dans le traitement de l'hyperplasie benigne de la prostate.
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
EP1173191A4 (fr) Nouveaux agents peptidiques anti-angiogeniques, utilisation de ces derniers pour la therapie et le diagnostic
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
EP0975651A4 (fr) Animaux transgeniques et lignees cellulaires pour le criblage de medicaments servant au traitement ou a la prevention de la maladie d'alzheimer
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
EP1100524A4 (fr) Utilisation d'uteroglobine humaine de recombinaison dans le traitement d'etats inflammatoires et de type fibreux
EP1214040A4 (fr) Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer
EP1572887A4 (fr) Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
EP1030680A4 (fr) Traitement de la maladie de kaposi avec il-12
LU90118B1 (fr) Utilisation de la mélatonine dans le traitement des patients souffrant d'accoutumance à certaines drogues

Legal Events

Date Code Title Description
ST Notification of lapse